Routine clinical use of nab-paclitaxel for advanced / metastatic breast cancer in Germany: Final results of the prospective observational study NABUCCO.

Schroeder, J., Potthoff, K., Salat, C., Soeling, U., Hansen, R., Grebhardt, S., Harde, J., Nusch, A., Marschner, N., 2017.

J Clin Oncol 35(suppl; abstr e12555). doi:10.1200/JCO.2017.35.15_suppl.e12555

Studie: NABUCCO; Indikation: Mammakarzinom; Jahr: 2017; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com